NF-κB, an Active Player in Human Cancers

  • Yifeng Xia
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California.
  • Shen Shen
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California.
  • Inder M. Verma
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California.

抄録

<jats:title>Abstract</jats:title> <jats:p>NF-κB comprises a family of five transcription factors that form distinct protein complexes, which bind to consensus DNA sequences at promoter regions of responsive genes regulating cellular processes. The past three decades have witnessed remarkable progress in understanding the NF-κB signaling pathway in physiologic and pathologic conditions. The role of NF-κB in human cancer initiation, development, metastasis, and resistance to treatment has drawn particular attention. A significant number of human cancers have constitutive NF-κB activity due to the inflammatory microenvironment and various oncogenic mutations. NF-κB activity not only promotes tumor cells' proliferation, suppresses apoptosis, and attracts angiogenesis, but it also induces epithelial–mesenchymal transition, which facilitates distant metastasis. In certain circumstances, NF-κB activation may also remodel local metabolism and anergize the immune system to favor tumor growth. Suppression of NF-κB in myeloid cells or tumor cells usually leads to tumor regression, which makes the NF-κB pathway a promising therapeutic target. However, because of its vital role in various biologic activities, components of the NF-κB pathway need to be carefully selected and evaluated to design targeted therapies. Cancer Immunol Res; 2(9); 823–30. ©2014 AACR.</jats:p>

収録刊行物

  • Cancer Immunology Research

    Cancer Immunology Research 2 (9), 823-830, 2014-09-01

    American Association for Cancer Research (AACR)

被引用文献 (12)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ